GleamWall
中文EN

XLO Xilio Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1840233 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY73.0%
TTM net income YoY80.4%
TTM EPS YoY103.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-74.9%
Net margin-20.9%
FCF margin-104.8%
EBITDA margin-72.6%

Returns

ROE-38.2%
ROA-8.6%
ROIC (approx.)—
Asset turnover0.41x

Leverage & solvency

Liabilities / assets49.4%
Debt / equity0.00x
Current ratio4.72x
Interest coverage—

Cash quality & payout

Operating cash flow / net income4.95x
Accruals ratio33.8%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$9.98M$18.69M$12.65M$13.69M$19.07M$8.08M$2.93M$1.72M
R&D expense$14.80M$14.56M$19.83M$18.12M$14.32M$15.33M$8.27M$8.84M
SG&A expense$6.93M$7.62M$6.93M$7.40M$6.67M$7.12M$8.52M$6.52M
Operating income-$11.75M-$3.49M-$14.11M-$11.84M-$1.93M-$14.37M-$13.85M-$13.63M
Net income-$5.95M-$6.37M-$9.53M$10.36M-$16.29M-$15.84M-$13.27M-$13.09M
EBITDA-$11.45M-$3.19M-$13.77M-$11.51M-$1.63M-$13.97M-$13.35M-$13.25M
EPS (basic)-0.30-0.33-0.58—-1.58-2.30-2.49—
EPS (diluted)-0.30-0.33-0.58—-1.58-2.30-2.49—
Balance sheet
Cash & equivalents$122.18M$136.04M$150.33M$137.53M$103.76M$121.55M$89.07M$57.07M
Current assets$126.50M$145.47M$154.21M$145.03M$124.09M$123.72M$93.20M$60.23M
PP&E, net$3.09M$3.36M$3.68M$3.89M$3.68M$4.02M$4.29M$4.47M
Total assets$134.83M$154.25M$163.49M$154.69M$133.69M$133.81M$103.72M$71.08M
Current liabilities$26.80M$34.20M$42.96M$56.27M$56.40M$53.26M$47.64M$27.26M
Total liabilities$66.60M$81.99M$90.94M$119.41M$141.79M$126.74M$93.02M$53.48M
Shareholders' equity$68.23M$72.26M$72.55M$35.27M-$8.10M$7.07M$10.70M$17.60M
Shares outstanding6.59M6.58M5.78M4.53M51.83M51.83M51.78M3.27M
Cash flow statement
Operating cash flow-$13.79M-$18.76M-$22.34M-$2.00M-$17.50M-$14.48M$28.98M-$14.16M
Capital expenditure$58,000$19,000$556,000$95,000$0$401,000$22,000$6,000
Free cash flow-$13.85M-$18.78M-$22.90M-$2.09M-$17.50M-$14.88M$28.96M-$14.16M
Investing cash flow-$58,000-$19,000-$556,000-$95,000$0-$401,000-$22,000-$6,000
Financing cash flow$0$4.49M$35.71M$35.87M-$285,000$47.36M$4.83M$8.20M
Depreciation & amortization$300,000$300,000$344,000$323,000$300,000$400,000$497,000$376,000
Stock-based compensation$1.92M$1.60M$2.21M$2.93M$1.12M$1.35M$1.53M$1.52M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.